[30 July 2017] The IBTA’s monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.
You can read the IBTA e-News July 2017 edition in full online here.
Some of the highlights from this month’s include:
- A comprehensive analysis of the entire genetic sequence of medulloblastoma tumours that has revealed the genetic changes that drive over 75% of the tumours.
- Research showing unequal access to brain tumour treatment in Argentina.
- The development of a new screening method to detect hitherto unseen brain tumour drug targets.
- A meta-analysis of 65 studies that has revealed the overall survival of paediatric participants with high grade brain stem gliomas (such as DIPG) is two years is just 15.3%..
- A special focus on upcoming and ongoing clinical trials that are open to patient enrollment, including a new arm of a phase 1b trial of Optune (a wearable Tumor Treating Fields device), the Pediatric MATCH ‘precision medicine’ trial, a recurrent anaplastic astrocytoma phase 3 trial (STELLAR) and a phase 1 trial of the gene therapy Ad-RTS-hIL-12 plus veledimex in recurrent glioblastoma.
- The publication of the 2017 policy report from All.Can, Towards sustainable cancer care: Reducing inefficiencies and improving outcomes, in the Journal of Cancer Policy.
- A study offering potential explanations for why glioblastoma risk is increased in people with Alzheimer’s disease.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.
